Skip to main content

Advertisement

Table 2 Mortality rates by potential baseline risk factors

From: Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study

Factor Level n Deaths Mortality rate per 100 person-years (95% C.I.)
Sex Male 422 69 8.0 (6.3; 10.2)
  Female 1031 128 5.7 (4.8; 6.8)
Age ≤ 30 251 41 8.7 (6.4; 11.8)
  31 to 40 670 83 5.8 (4.7; 7.2)
  > 40 532 73 6.2 (4.9; 7.7)
WHO stage I 20 1 2.3 (0.3; 16.0)
  II 642 55 3.8 (2.9; 5.0)
  III 673 109 7.8 (6.5; 9.4)
  IV 118 32 14.9 (10.5; 21.0)
Baseline CD4 count cells/mm3 <50 444 110 13.0 (10.8; 15.6)
  50-99 232 20 3.9 (2.5; 6.0)
  100 - 149 306 33 4.9 (3.5; 6.9)
  150 - 199 339 21 2.8 (1.8; 4.2)
  ≥ 200 132 13 4.5 (2.6; 7.7)
Baseline plasma viral load copies/ml <1,000 21 3 6.7 (2.2; 20.7)
  1,000 - 9,999 40 2 2.6 (0.6; 10.3)
  10,000 -99,999 454 49 4.9 (3.7; 6.5)
  100,000 -999,999 832 130 7.4 (6.3; 8.8)
  >1,000,000 106 13 5.7 (3.3; 9.9)
Weight (kg) * < 50 431 94 11.0 (9.0; 13.4)
  50 - 60 698 76 5.0 (4.0; 6.3)
  > 60 317 22 3.0 (2.0; 4.6)
Haemoglobin (g/dl) ≥ 11 701 76 5.0 (4.0; 6.3)
  9.5 - 10.9 407 64 7.4 (5.8; 9.5)
  8.0 - 9.4 242 37 7.4 (5.3; 10.2)
  6.5 - 7.9 80 12 6.7 (3.8; 11.7)
  <6.5 19 6 19.2 (8.6; 42.8)
  Missing 4 2  
On cotrimoxazole prophylaxis Yes 1403 185 6.2 (5.3; 7.1)
  No 50 12 12.0 (6.8; 21.1)
Study Arm Facility Based 594 80 6.5 (5.2; 8.1)
  Home Based 859 117 6.3 (5.2; 7.5)
Time following initiating ART 0 - 5 months 1453 112 16.5 (13.7; 19.8)
  6 - 11 months 1296 42 6.7 (5.0; 9.1)
  12 - 23 months 1168 32 3.0 (2.2; 4.3)
  24 - 35 months 872 8 1.3 (0.7; 2.6)
  ≥ 36 months 314 3 2.4 (0.8; 7.6)
  1. * Weight was missing for 7 people of whom 5 died.